Merck Serono S.A.S, France
8
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
12.5%
1 terminated/withdrawn out of 8 trials
87.5%
+1.0% vs industry average
50%
4 trials in Phase 3/4
86%
6 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
PERgoveriS In Stratified Treatment for Assisted Reproductive Technique
Role: collaborator
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
Role: collaborator
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France
Role: collaborator
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
Role: collaborator
A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)
Role: collaborator
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
Role: collaborator
EXpression PRofile Endometrium Samples Study
Role: collaborator
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
Role: collaborator
All 8 trials loaded